BB Biotech AG (BBAGF) Fund Overview
BB Biotech AG (BBAGF) — price $64.36 (+5.20%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
BB Biotech AG · BBAGF
BB Biotech AG is a Swiss-based investment company specializing in biotechnology investments. The company's strategy focuses on identifying and investing in companies with promising medications and diagnostics.
Price as of Oct 2, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $64.36 |
| Change on the day | +5.20% |
| 52-week range | $33.65 – $76.06 |
| Price / earnings (trailing) | 2.05 |
| Shares traded on the day | 5 |
Price & events
Other perspectives
Council score for BB Biotech AG (BBAGF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the BBAGF film — every key number, told as a short cinematic story
~2 min · open the film
What is BB Biotech AG (BBAGF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BB Biotech AG (BBAGF) is the company analyzed here. It employs 10 people and is led by Daniel Koller. In Q2 FY2026 it reported revenue of CHF 109M and net income of CHF 449M.
What do the latest results show for BB Biotech AG (BBAGF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CHF 109M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CHF 109M | CHF 449M | CHF 7.97 (diluted) |
| Q1 FY2026 | CHF 35M | -CHF 21M | -CHF 0.38 (diluted) |
| Q4 FY2025 | CHF 475M | CHF 472M | CHF 8.62 (diluted) |
| Q3 FY2025 | CHF 21M | CHF 447M | CHF 8.15 (diluted) |
What are the financial strengths and risks for BB Biotech AG (BBAGF)?
Short answer
The distress and quality screens read Piotroski F 5. Trailing ratios: ROE -12.2% · ROA -10.7% · earnings yield -12.2% · free-cash-flow yield 16.7%.
Investor Questions: BBAGF Stock
These answers are editorial: 1 of these 1 answer is drawn from the BBAGF research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for BBAGF?
The main risks for BB Biotech AG (BBAGF) include regulatory and clinical trial risks associated with the biotechnology sector. The success of its portfolio companies depends on obtaining regulatory approvals and achieving positive clinical trial outcomes.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (13 figures)
The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $64.36 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T07:35:07.770Z. | |
px.change | Change on the day | +5.20% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | +$3.18 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 2.05 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | CHF 109M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | CHF 449M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $33.65 – $76.06 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 10 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Daniel Koller | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
fin.scores | Distress and quality screens | Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -12.2% · ROA -10.7% · earnings yield -12.2% · free-cash-flow yield 16.7% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.